Amgen's Double Beat and Above-Street 2026 Guide Reprice the Stock 8%; MariTide Remains the Whole Ballgame

Results vs. Consensus

Year-over-year comparison (Q4'25 vs. Q4'24)

Full-year 2025 vs. 2024

Quality of Beat/Miss

• Revenue: High quality. The $9,866M print was driven by 10% volume growth across Repatha, Evenity, Tezspire, Uplizna and the oncology BiTE platform, partly offset by 4% lower net selling price. Other revenue jumped ~35% to $499M. There was no single one-time item inflating the number; if anything, a ~$250M inventory build in 2025 that management flagged could reverse and pressure Q1 2026.
• Margins: Lower quality on the surface, but by design. Non-GAAP operating margin of 42.8% (down 3.5pp) reflects record R&D (+22% YoY to $7.2B for the year, including ~$300M of business-development spend closed in Q3/Q4). This is discretionary reinvestment, not cost inflation, which makes it a policy choice the market can underwrite or penalize depending on pipeline conviction.
• EPS: The $5.29 non-GAAP number beat comfortably but was flat YoY, so the beat was against a de-risked Street bar rather than evidence of earnings acceleration. Note the wide GAAP-to-non-GAAP gap ($2.45 vs. $5.29), driven by Horizon-related amortization and, for the full year, a $1.2B Otezla intangible impairment tied to IRA Medicare price setting. GAAP EPS optics (+111% in Q4) are distorted by equity-investment mark-to-market swings and should be discounted.

Segment Performance

Amgen reports one product-sales line but manages four therapeutic areas. The table below aggregates the most material Q4 franchises; the subsections that follow assess each therapeutic area and its trajectory into 2026.

General Medicine — the engine, carried by Repatha and Evenity

General Medicine generated over $11B for the full year and was the standout in Q4. Repatha grew 44% YoY to $870M, aided by 31% volume growth, an 8% net-price benefit, and higher inventory. Evenity rose 39% to $599M, beating the $559M Street bar and holding better than 60% share of the bone-builder segment. The offset within the segment is Prolia, which fell 10% to roughly $1.1B as denosumab biosimilars begin to land; management explicitly guided to accelerated Prolia erosion in 2026.

"Repatha remains the first and only PCSK9 inhibitor with outcomes data for patients in both high-risk primary and secondary prevention." — Murdo Gordon, EVP, Global Commercial Operations

Assessment: Repatha and Evenity are doing exactly what a growth-offset portfolio needs to do, and Repatha's price actually helped this quarter, which is rare for Amgen. But the segment's net trajectory into 2026 is a tug-of-war: two 30%+ growers versus an accelerating denosumab cliff. The bull needs Repatha and Evenity to out-run Prolia, and Q4 says they can, at least for now.

Rare Disease — the highest-growth engine, led by Uplizna

The rare-disease portfolio (largely the Horizon assets plus Tavneos) grew 19% in the quarter and ~14% for the year to nearly $5.2B. Uplizna was the headliner, up 131% YoY to $233M with a fresh generalized myasthenia gravis approval in December layered on top of NMOSD and IgG4-related disease. Krystexxa rose 26% to $435M. Tepezza was roughly flat at $457M, held back by inventory timing and sales-deduction changes rather than demand.

"Uplizna sales increased 73% year over year to $655 million, reflecting growing patient demand across all three approved indications." — Murdo Gordon, EVP, Global Commercial Operations

Assessment: This is the cleanest growth story in the portfolio and the strategic justification for the Horizon acquisition. Uplizna's CD19 B-cell-depletion mechanism is being pushed into autoimmune hepatitis and CIDP, giving it a multi-indication runway. The overhang here is Tavneos (below), not the growth engine itself.

Inflammation — Tezspire shining, Enbrel and Otezla eroding

Inflammation topped $7B for the year. Tezspire is the bright spot, up 60% to $474M and now the leading new-to-brand therapy among allergists in severe uncontrolled asthma, with Phase 3 readouts in COPD and eosinophilic esophagitis due in 2H26. The legacy assets are the drag: Enbrel fell 48% to $532M on price, 340B mix and Part D redesign and missed the $636M Street bar, and Otezla was flat at $625M with a $1.2B full-year impairment after being selected for IRA Medicare price setting.

"Tezspire is now the leading therapy for new-to-brand patients amongst allergists in severe uncontrolled asthma." — Murdo Gordon, EVP, Global Commercial Operations

Assessment: Tezspire is a genuine multi-billion-dollar franchise-in-the-making with respiratory label-expansion optionality, and it is split economics with AstraZeneca. Enbrel and Otezla are managed-decline assets whose erosion is well telegraphed; the risk is pace, not direction. Net, the segment's growth is increasingly a Tezspire story.

Oncology — BiTE platform maturing, biosimilars offsetting

Innovative oncology grew 11% for the year to $8.7B. Imdelltra is the new engine: $234M in Q4, up 31% sequentially, following full FDA approval in November as second-line standard of care in small cell lung cancer. Blincyto crossed $1.5B for the year (+28%) though Q4's $413M missed the $434M bar. The offsets are the mature/biosimilar-exposed lines: Kyprolis fell 6% to $351M and Xgeva fell 20% to $447M on biosimilar competition.

"It's a joy to see Imdeltra, like Blincyto, becoming a standard of care in the management of advanced cancer." — James Bradner, EVP, R&D

Assessment: The bispecific T-cell-engager platform (Blincyto, Imdelltra, and the Phase 3 prostate asset xaluritamig) is the durable oncology thesis, and Imdelltra's sequential ramp is the number to watch. Xgeva's decline mirrors Prolia's, so denosumab erosion shows up twice in the model. Oncology is a net grower but not a needle-mover at the corporate multiple.

Biosimilars — quietly compounding

Biosimilars grew 37% for the year to $3.0B, with Pavblu (an EYLEA biosimilar) reaching $700M in its first full year and the next wave (ABP 206 to Opdivo, ABP 234 to Keytruda) completing comparative enrollment.

Assessment: This is a durable, cash-generative business that the market largely ignores in the valuation. It will not re-rate the stock, but it funds the pipeline and diversifies away from the LOE cliffs. A quiet positive.

Key Topics & Management Commentary

Overall Management Tone: Management was confident and on-message, treating 2025 as a "track record intact" year and 2026 as a "springboard," with the CEO framing six named growth drivers as multi-year, not one-year, stories. The posture was most assured on Repatha and MariTide and most defensive on Tavneos, where the team was visibly working to reassure after an unusual FDA withdrawal request. There was no hedging on the R&D ramp; management leaned into it as deliberate.

1. MariTide — the obesity asset that defines the equity

Everything else in this report is context; MariTide (maridebart cafraglutide, AMG 133) is the swing factor. Six global Phase 3 studies are now running: MARITIME-1 and -2 for chronic weight management are fully enrolled, cardiovascular (MARITIME-CV) and heart-failure (MARITIME-HF) outcomes studies are enrolling, two sleep-apnea studies have started, and a Type 2 diabetes Phase 3 is slated to begin later in 2026. The differentiation management keeps returning to is dosing frequency.

"Meritide stands alone as the only therapy in late-stage development to offer the paradigm-changing prospect of strong efficacy and favorable tolerability at monthly, every other month, or even quarterly dosing." — Robert Bradway, Chairman & CEO

Phase 2 data completed in the quarter showed the large majority of patients maintaining weight loss for an additional 52 weeks on lower monthly or quarterly doses, with a low incidence of nausea and vomiting and no new safety signals. Management also disclosed a second internal obesity asset, AMG 513, now in Phase 1.

Assessment: The monthly/quarterly maintenance profile is a genuinely differentiated angle in a field crowded with weekly injectables and emerging orals, and the tolerability data are the most important disclosure of the quarter. But this is optionality, not earnings: the pivotal weight-management data have not read out, the competitive bar (efficacy versus incumbents) is high, and Amgen's own history with AMG 133 tolerability at higher doses is the reason the maintenance-dosing story matters so much. This is why we start at Hold rather than Outperform.

2. Repatha and the VESALIUS-CV inflection

The most important commercial event of the quarter is the VESALIUS-CV readout. In more than 12,000 patients with atherosclerosis or diabetes but no prior heart attack or stroke, Repatha delivered a 25% relative risk reduction in the composite of coronary-heart-disease death, heart attack or ischemic stroke, and a 36% reduction in heart attack, with no new safety signals.

"These data clearly demonstrate that intensive LDL-C lowering with Repatha can meaningfully reduce the risk of a first cardiovascular event." — James Bradner, EVP, R&D

Management is now positioning Repatha for primary prevention, where roughly 40% of prescriptions already originate, and is pushing for guideline and quality-measure changes. Amgen Now, a direct-to-patient cash-pay channel, is being expanded to additional medicines and onto Trump Rx.

Assessment: VESALIUS-CV is the rare late-life-cycle catalyst that expands a drug's addressable population rather than defending it. The 44% Q4 growth suggests the inflection is real. The offset is Merck's oral PCSK9 entering the market; management's defense (only Repatha has both primary and secondary prevention outcomes data) is credible but will be tested on convenience.

3. The 2026 guide and Q1 seasonality

The 2026 revenue guide of $37.0B–$38.4B (midpoint $37.7B) sits ~$0.8B above the ~$36.9B Street, and the EPS guide of $21.60–$23.00 (midpoint $22.30) sits above the ~$21.85 consensus. The CFO was careful to pre-warn on Q1.

"For total company revenues, we expect lower mid-single-digit year-over-year growth in the first quarter... we saw roughly $250 million of inventory build in 2025 that could potentially impact first-quarter sales." — Peter Griffith, EVP & CFO

Assessment: A guide above the Street on both lines is the single biggest reason the stock rallied. But the Q1 framing (seasonal insurance-cycle headwinds, the lowest operating margin of the year, an inventory-build reversal, incremental denosumab erosion) sets up a soft-looking Q1 print that could re-open the "is growth actually accelerating?" debate. Smart to pre-warn; it caps the Q1 downside.

4. R&D reinvestment and the margin trade

Full-year non-GAAP R&D rose 22% to a record $7.2B, and Q4 operating margin fell 3.5pp to 42.8%. Management frames this as investing across "an unprecedented number of opportunities" in the late-stage pipeline, and guides 2026 R&D to grow only low-single-digits ex the ~$300M of 2025 business development.

"This reflects increased spending on an unprecedented number of opportunities in our late-stage pipeline, including continued investments in MariTide, olpasiran, xaluritamig, and rare disease." — Peter Griffith, EVP & CFO

Assessment: The reinvestment is the reason EPS was flat despite a revenue beat, and it is the crux of the bull/bear split. If MariTide and olpasiran hit, this spend looks visionary; if they disappoint, 2025–26 will read as a margin air-pocket with little to show. The low-single-digit 2026 R&D guide is a tell that the heaviest step-up is now in the base.

5. Denosumab loss of exclusivity (Prolia & Xgeva)

Prolia (~$1.1B, -10%) and Xgeva ($447M, -20%) are both in the early innings of biosimilar erosion, with patents having expired in the US in February 2025 and in parts of Europe in November 2025. Management guided to accelerated erosion for both in 2026.

Assessment: Denosumab is the clearest visible headwind in the model and it shows up twice (bone health and oncology supportive care). The combined franchise is a multi-billion-dollar base that will decline for several years. The 2026 guide already embeds this, which is why an above-Street guide despite the denosumab cliff is genuinely reassuring.

6. Tavneos and the FDA withdrawal dispute

The most unusual disclosure of the quarter: on January 16, 2026, the FDA requested that Amgen voluntarily withdraw Tavneos (avacopan, for ANCA-associated vasculitis) over concerns about ChemoCentryx's process to re-adjudicate primary-endpoint results for 9 of 331 patients in the pivotal trial. On January 28, Amgen informed the FDA it would not withdraw.

"As we shared, the FDA requested a voluntary withdrawal on January 16. We were surprised by this... We're in discussions with FDA and we'll answer questions as we talk with them." — James Bradner, EVP, R&D

Assessment: Tavneos is small (FY sales $459M), so the direct financial stakes are modest. The read-through risk is reputational and precedent-setting: a public standoff with the FDA over trial-data adjudication is not a place a large-cap pharma wants to be. Low P&L impact, non-trivial headline risk. We treat it as a contained, monitorable overhang.

7. Oncology BiTE platform durability

Imdelltra's full approval and 31% sequential ramp, plus Blincyto crossing $1.5B, validate the bispecific T-cell-engager platform. The Phase 3 STEAP1-directed asset xaluritamig in prostate cancer extends the platform into a large solid-tumor indication.

Assessment: The BiTE platform is the most credible internally-developed oncology franchise Amgen has, and Imdelltra becoming SCLC standard of care is a real clinical win. It is a steady grower rather than a re-rating catalyst, but it de-risks the oncology base against biosimilar erosion.

8. Olpasiran and the Lp(a) opportunity

Olpasiran, the Lp(a)-lowering siRNA, remains in the fully-enrolled OCEAN(a) outcomes study, but management flagged that event accrual is running slower than initial predictions and declined to give a firm primary-analysis date.

"The aggregate endpoint accrual rate remains lower than initial predictions. As the study matures, we will update on the date for primary analysis as appropriate." — James Bradner, EVP, R&D

Assessment: Slower event accrual pushes the olpasiran catalyst further right and is a modest negative for the cardiometabolic narrative that pairs Repatha, olpasiran and MariTide. Conviction in the mechanism is unchanged; the timeline is fuzzier.

9. Otezla and IRA price-setting

Otezla was selected for Medicare price setting under the Inflation Reduction Act, triggering a $1.2B full-year GAAP intangible impairment. Q4 sales were roughly flat at $625M.

Assessment: This is a concrete example of IRA policy risk landing on a specific asset. Otezla was already a managed-decline story; the impairment formalizes it. The read-through is that Amgen, like all large-cap pharma, now carries a recurring IRA overhang on its more mature Medicare-exposed brands.

10. Capital allocation and the balance sheet

Amgen generated $8.1B of free cash flow (down from $10.4B on working-capital timing and higher capex), retired $6B of debt, and exited 2025 at roughly 3.2x EBITDA leverage. The Q4 dividend was $2.38/share (+6%), and 2026 guidance caps buybacks at $3B with capex rising to ~$2.6B.

Assessment: Deleveraging from the Horizon deal is progressing, but 3.2x is still elevated for a company also funding record R&D and a rising capex bill. The modest buyback cap and 6% dividend growth signal that capital priorities are pipeline and balance sheet first, shareholder returns second. Appropriate, but it limits the per-share compounding story.

11. Portfolio discipline — what they walked away from

Management pruned two programs: it terminated the rocatinlimab collaboration (returning the asset to Kyowa Kirin) and decided not to pursue bemarituzumab in first-line gastric cancer after the FORTITUDE-101/-102 readouts, while noting a possible survival signal in a biomarker-defined subset.

Assessment: Cutting two late-stage programs to concentrate resources is the right instinct given the breadth of the pipeline, and it lends credibility to the R&D ramp being about prioritization rather than spending for its own sake. A quiet positive for capital discipline.

Guidance & Outlook

The 2026 guide is the reason the stock worked. A revenue midpoint $0.8B above consensus and an EPS midpoint $0.45 above consensus, delivered while absorbing accelerating denosumab erosion, tells the market the growth portfolio (Repatha, Evenity, Tezspire, rare disease, oncology, biosimilars) is out-running the LOE cliff. Management's qualitative framing was that 2026 is a "springboard" year, i.e., a base for the pipeline-driven acceleration they expect later in the decade.

Implied ramp: The revenue midpoint implies ~+3% growth over 2025's $36.75B, which is modest, but the shape matters: Q1 was explicitly guided to "lower mid-single-digit" growth with the lowest margin of the year, implying a back-half-weighted year as denosumab laps and growth brands compound.

Street at: Consensus was below the guide midpoint on both lines going in, so numbers move up modestly. Expect the debate to shift from "is the guide credible?" to "how conservative is it?"

Guidance style: Consistent with Amgen's historical pattern of guiding to a range it intends to beat; the CFO's Q1 pre-warning is classic expectation-management. Note the guide excludes any 2026 business development, which is a standing source of upside (and R&D risk).

Analyst Q&A Highlights

Obesity portfolio breadth beyond MariTide

The opening question pressed on how Amgen intends to compete across the full obesity landscape given rivals are disclosing combinations and monthly regimens, and whether MariTide alone is enough. Management leaned into breadth, pointing to a second clinical asset and a preclinical incretin/non-incretin pipeline.

Q: "I was wondering... your view of the portfolio overall in obesity given that folks like [competitors] are disclosing combinations with monthly... and how you see this playing out given you're focused on MariTide, but not so sure about the rest of the portfolio there."
— Michael Yee, UBS

A: "Internally, we have another clinical stage asset called AMG 513... And preclinically, we have a rather exciting set of rising programs that are both incretin based as well as non-incretin based, of both injectable as well as oral medicines. And the aperture is always open for innovation on the outside. I think you should expect us to be competing broadly in the field."
— James Bradner, EVP, R&D

Assessment: Management wants investors to see obesity as a franchise, not a single molecule, but the honest read is that everything beyond MariTide is early-stage. The "aperture is always open... on the outside" line is a hint that obesity business development is on the table, which would be a use of the balance sheet the market would scrutinize.

The efficacy-versus-frequency trade-off in MariTide dosing

A recurring line of questioning probed whether pushing MariTide beyond monthly dosing necessarily sacrifices efficacy, and what minimum efficacy bar the market would require. Management pushed back on the premise itself.

Q: "As you're thinking about just pushing the program beyond monthly, what profile do you think you'd need to see for that to have a role in the market? Are there minimum efficacy bars you're looking at?"
— Chris Schott, JPMorgan

A: "I'm going to reject part of the premise of your question, this idea of less frequent dosing being an absolute tradeoff for efficacy. We're not certain that we will see that. Having observed the large majority of patients maintaining weight on low dose and on quarterly dosing... I wouldn't necessarily assume that we'll see a big tradeoff with less frequent dosing of MariTide."
— James Bradner, EVP, R&D

Assessment: This is the most important exchange on the call. Management is betting that the "defended fat mass" concept means maintenance dosing can be de-coupled from efficacy loss, which, if borne out in Phase 3, is the entire differentiation. It is also an unproven hypothesis, and the confidence of the answer will be graded directly against the pivotal data.

Type 2 diabetes CVOT trial design

A question sought detail on the control-arm design for the planned MariTide Type 2 diabetes cardiovascular-outcomes trial, an area management had signaled it was still working through. The answer confirmed the program is moving to Phase 3 but declined to specify the design.

Q: "Just was wondering if you have any update in terms of how to think about the design of the MariTide Phase 3 Type 2 diabetes CVOT trial, particularly the control arm."
— Terence Flynn, Morgan Stanley

A: "The robust findings of this trial position us very well to start to pursue Phase 3 clinical investigation. The specific design of these studies, control arms and the patients recruited, will be a subject for a future engagement."
— James Bradner, EVP, R&D

Assessment: A polite deferral. The T2D CVOT is a large, expensive, long-duration commitment, and the control-arm choice (against standard of care versus an active GLP-1 comparator) materially affects both cost and the strength of the eventual label. Management is keeping its options open, which is reasonable but leaves a modeling gap.

Uplizna's expansion into CIDP and the Repatha competitive response

A two-part question asked what gives management confidence to advance Uplizna into a CIDP Phase 3, and separately how Amgen adapts Repatha's commercial strategy to Merck's oral PCSK9. Management tied Uplizna's confidence to its CD19 mechanism and defended Repatha on its outcomes-data breadth.

Q: "Walk us through what's given you confidence here in moving forward with a Phase 3 study in CIDP... And separately just touch on Repatha and how you're thinking about potential impact from the launch of Merck's oral PCSK9."
— Salveen Richter, Goldman Sachs

A: "We are the only PCSK9 that has both secondary and primary prevention data in our label... We've maintained all along that there is a lot of room in this market for other therapies to come in, but they will not have the data package and profile that Repatha has established."
— Murdo Gordon, EVP, Global Commercial Operations

Assessment: The Repatha defense is grounded in a real differentiator (outcomes data across both prevention settings), but an oral will compete on convenience, not just data. Management's confidence that the market is large enough for both is plausible given roughly 100 million patients still needing LDL lowering, but share dynamics post-oral launch are a genuine 2026–27 watch item.

Repatha's primary-care mix after VESALIUS-CV

A question asked what share of Repatha prescriptions now come from primary care and how VESALIUS-CV changes that mix over time. Management quantified the current split and signaled it expects primary-care penetration to grow.

Q: "Can you please remind us what percentage of your prescriptions are coming from primary care at this point? And with the VESALIUS data, how do you see the primary care segment of the market evolving over time?"
— Mohit Bansal, Wells Fargo

A: "Roughly 40% of our prescriptions were coming from patients who were considered primary prevention... I would imagine that that will increase and grow over time. What we're seeing is equal interest quite frankly from cardiologists who are excited by the VESALIUS data."
— Murdo Gordon, EVP, Global Commercial Operations

Assessment: The 40% primary-prevention mix is a concrete data point that supports the inflection thesis: the addressable prescriber base is broadening from cardiology to primary care. This is the mechanism by which VESALIUS-CV converts into sustained volume, and Q4's 44% growth is the early evidence.

The Tavneos / FDA standoff

The most pointed exchange of the call sought to understand what prompted the FDA's withdrawal request and whether the re-adjudicated patients even affected the primary endpoint. Management reframed at a high level and acknowledged it was surprised.

Q: "I'm really lost today. Why did FDA decide to ask you to pull the ChemoCentryx drug?... they're saying that nine patients need to be readjudicated. Is that referring to the primary endpoint on week 26 remission or the week 52 sustained remission? Because week 26 endpoint was not inferior anyway."
— Umer Raffat, Evercore ISI

A: "As we shared, the FDA requested a voluntary withdrawal on January 16. We were surprised by this. There were concerns raised about a process followed by ChemoCentryx to readjudicate primary endpoint results for nine of the 331 patients. And we're in discussions with FDA and we'll answer questions as we talk with them."
— James Bradner, EVP, R&D

Assessment: Management did not fully answer the technical question (which endpoint, and whether the non-inferiority conclusion survives re-adjudication), which is understandable mid-negotiation but leaves the overhang unresolved. The stakes are small financially and larger reputationally. This is the one place the call sounded defensive.

Pavblu biosimilar leadership durability

A question probed how Amgen sustains its Pavblu (EYLEA biosimilar) lead as additional biosimilars launch in the second half of 2026. Management declined product-level guidance but pointed to device and network advantages.

Q: "You had a strong quarter with Pavblu. How do you expect to maintain this leadership position when other manufacturers launch biosimilars in the second half of the year?"
— Alex Hammond, Wolfe Research

A: "We've been able to... establish good inroads with the largest national retina specialist networks... We think we've got a great device that helps them... and given that we have a lot of biosimilar experience, we'll compete effectively when others enter the market, whenever that may be."
— Murdo Gordon, EVP, Global Commercial Operations

Assessment: A reasonable answer that leans on Amgen's structural biosimilar advantages (manufacturing scale, prefilled-syringe device, payer relationships). Pavblu at $700M in year one is a genuine success, but second-half competition will test the durability of the lead, and management pointedly would not commit to a growth number.

What They're NOT Saying

1. No MariTide Phase 3 efficacy data: Management talked extensively about dosing frequency and tolerability but has not put pivotal weight-management efficacy numbers on the table. Until those read out, the obesity thesis rests on Phase 2 and confidence, not proof.
2. No product-level MariTide or 2026 franchise guidance: Amgen declined to size the obesity opportunity or give per-product 2026 numbers, so the market is left to triangulate the guide's composition against an accelerating denosumab cliff.
3. The Tavneos endpoint question went unanswered: Management would not say whether the re-adjudication affects the primary-endpoint conclusion, leaving the analytical core of the FDA dispute opaque.
4. Olpasiran's primary-analysis date: Management explicitly declined to provide a timeline given slower-than-expected event accrual, pushing a key cardiometabolic catalyst into an undefined window.
5. The pace of denosumab erosion: Management guided to "accelerated" Prolia/Xgeva erosion but did not quantify it, which is the single largest swing factor inside the 2026 revenue guide.
6. Otezla's forward trajectory: Beyond flagging IRA price-setting and the impairment, management said little about how quickly Otezla declines from here.

Market Reaction

• Pre-print setup: AMGN closed at $338.59 on 2026-02-03 entering the print, up ~3.4% YTD, up ~3.3% over the trailing 30 days, and up ~17.2% over the trailing 12 months. The stock entered near the top of its 52-week closing range of $262.28–$351.32.
• After-hours move: The immediate after-hours reaction on the evening of 2026-02-03 was muted and mixed (web sources cited roughly flat to -0.4%), as the first reaction weighed the Tavneos/FDA overhang and flat YoY EPS against the beat.
• Reaction-day session: On 2026-02-04 the stock repriced sharply higher, opening at $352.03 (+4.0% gap), trading as high as $368.75, and closing at $366.20, up 8.2% (+$27.61) on ~5.9M shares versus a 2.8M 30-day average (2.1x).
• Relative: The S&P 500 fell ~0.5% on the reaction day, so AMGN outperformed the tape by roughly 8.7 percentage points.

The move is best explained as the market digesting a clean double beat plus a 2026 guide above the Street on both revenue and EPS, layered on constructive MariTide maintenance-dosing data. The overnight hesitation and next-day rally pattern suggests the beat alone was priced, but the above-consensus guide and the reassurance that the growth portfolio out-runs the denosumab cliff is what re-rated the stock. The magnitude of the pop is precisely why we initiate at Hold rather than Outperform: a good quarter, now largely captured.

Street Perspective

Debate: Is MariTide a franchise or a single high-risk shot?

Bull view: The monthly/quarterly maintenance-dosing profile is genuinely differentiated in a field of weekly injectables and emerging orals, and with six Phase 3 studies plus a Phase 1 follow-on (AMG 513), Amgen is building an obesity platform, not betting on one molecule.

Bear view: Pivotal efficacy has not read out, the AMG 133 tolerability history at higher doses is the reason maintenance dosing is the pitch, and the competitive bar set by incumbents (and orals) is high. This is optionality that could round to zero.

Our take: The bull has the more interesting asset but the bear has the better risk framing today. Maintenance dosing without an efficacy penalty is a compelling hypothesis, but it is a hypothesis. We want to see the first pivotal weight-management data before paying for the franchise; that data is the event that would move us to Outperform.

Debate: Does the growth portfolio out-run the LOE cliff?

Bull view: An above-Street 2026 guide delivered while absorbing accelerating Prolia/Xgeva erosion is proof the six growth drivers (Repatha, Evenity, Tezspire, rare disease, oncology, biosimilars) already offset the cliff, with MariTide as free upside.

Bear view: The revenue guide midpoint implies only ~3% growth, denosumab erosion is guided to accelerate without being quantified, and Enbrel/Otezla keep shrinking, so the base is lower-growth than the "springboard" framing implies.

Our take: The bull is right that the guide is reassuring; the bear is right that ~3% growth is not a re-rating story on its own. Both can be true: the base is a low-to-mid-single-digit grower that is safe but not exciting, which is exactly a Hold profile absent MariTide.

Debate: Is the R&D margin compression a virtue or a warning?

Bull view: Record R&D (+22% to $7.2B) funds an unprecedented late-stage pipeline; management's willingness to spend and to prune (rocatinlimab, bemarituzumab) signals conviction and discipline, not distress.

Bear view: Flat YoY EPS despite a revenue beat is the tell: earnings growth has stalled while the company spends, and if the pipeline disappoints, 2025–26 is a margin air-pocket with a 3.2x-levered balance sheet underneath it.

Our take: The low-single-digit 2026 R&D guide suggests the heaviest step-up is now in the base, which caps the compression. We give management the benefit of the doubt on discipline, but flat EPS plus elevated leverage is why the stock deserves a pipeline-contingent multiple rather than a premium one.

Model Update Needed

Valuation impact: At the $366 reaction-day close, AMGN trades at roughly 16.4x the 2026 non-GAAP EPS midpoint of $22.30. That is a fair, not cheap, multiple for a low-to-mid-single-digit core grower with a levered balance sheet and a large but unproven obesity call option. We frame fair value in the high-$350s to high-$360s on the base business, with MariTide the source of asymmetric upside; a de-risking pivotal readout would justify a materially higher multiple. Net: the risk/reward is balanced here, consistent with a Hold.

Thesis Scorecard Post-Earnings

This is initiation of coverage, so the scorecard below establishes the standing thesis pillars we will grade in subsequent quarters.

Overall: The core business is durable and growing modestly, the growth brands are demonstrably out-running the LOE cliff, and the obesity optionality is real but unproven. The thesis is balanced: confirmed growth engine and confirmed headwinds, with one large unresolved swing factor.

Action: Initiate at Hold. Own the durability, respect the optionality, but do not pay an Outperform multiple until MariTide pivotal data begin to de-risk the call. Revisit on the first Phase 3 weight-management readout or a Q1 print that reframes the growth trajectory.